- Home
- PTY vs IBRX Comparison
PTY vs IBRX Comparison
Compare PTY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- IBRX
- Stock Information
- Founded
- PTY 2002
- IBRX 2014
- Country
- PTY United States
- IBRX United States
- Employees
- PTY N/A
- IBRX N/A
- Industry
- PTY Investment Managers
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTY Finance
- IBRX Health Care
- Exchange
- PTY Nasdaq
- IBRX Nasdaq
- Market Cap
- PTY 2.5B
- IBRX 2.4B
- IPO Year
- PTY N/A
- IBRX N/A
- Fundamental
- Price
- PTY $13.78
- IBRX $2.71
- Analyst Decision
- PTY
- IBRX Strong Buy
- Analyst Count
- PTY 0
- IBRX 5
- Target Price
- PTY N/A
- IBRX $11.40
- AVG Volume (30 Days)
- PTY 550.4K
- IBRX 11.3M
- Earning Date
- PTY 01-01-0001
- IBRX 05-12-2025
- Dividend Yield
- PTY 9.65%
- IBRX N/A
- EPS Growth
- PTY N/A
- IBRX N/A
- EPS
- PTY N/A
- IBRX N/A
- Revenue
- PTY N/A
- IBRX $31,222,000.00
- Revenue This Year
- PTY N/A
- IBRX $579.01
- Revenue Next Year
- PTY N/A
- IBRX $173.61
- P/E Ratio
- PTY N/A
- IBRX N/A
- Revenue Growth
- PTY N/A
- IBRX 10238.41
- 52 Week Low
- PTY $11.92
- IBRX $1.83
- 52 Week High
- PTY $14.88
- IBRX $7.63
- Technical
- Relative Strength Index (RSI)
- PTY 52.32
- IBRX 55.06
- Support Level
- PTY $13.58
- IBRX $2.43
- Resistance Level
- PTY $13.72
- IBRX $2.79
- Average True Range (ATR)
- PTY 0.10
- IBRX 0.22
- MACD
- PTY -0.00
- IBRX 0.02
- Stochastic Oscillator
- PTY 48.65
- IBRX 54.61
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.